000			03095nam a22004457a 4500
008			201006s20202020 xxu||||| |||| 00| 0 eng d
022			_a1053-2498
024			_a10.1016/j.healun.2020.06.024 [doi]
024			_aS1053-2498(20)31646-6 [pii]
040			_aOvid MEDLINE(R)
099			_a32883559
245			_aReport from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.
251			_aJournal of Heart & Lung Transplantation. 39(10):1050-1069, 2020 10.
252			_aJ Heart Lung Transplant. 39(10):1050-1069, 2020 10.
252			_zJ Heart Lung Transplant. 39(10):1050-1069, 2020 Oct.
253			_aThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
260			_c2020
260			_fFY2021
265			_sppublish
266			_d2020-10-06
268			_aJournal of Heart & Lung Transplantation. 39(10):1050-1069, 2020 Oct.
501			_aAvailable online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007
520			_aIn 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation. Copyright (c) 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
546			_aEnglish
650			_a*Consensus
650			_a*Drugs, Generic/pd [Pharmacology]
650			_a*Graft Rejection/pc [Prevention & Control]
650			_a*Immunosuppression/mt [Methods]
650			_a*Immunosuppressive Agents/pd [Pharmacology]
650			_a*Lung Transplantation
650			_aDrug Substitution
650			_aHumans
651			_aMedStar Washington Hospital Center
656			_aPharmacy
657			_aEditorial
700			_aPeters, Lisa
790			_aBaran D, Claridge T, Cochrane AB, Colvin M, Dawson K, Dipchand A, Doligalski C, Ensor CR, Flattery M, Ford K, Girgis R, Ivulich S, Jennings D, Khuu T, Kittleson M, Lindenfeld J, Lyster H, Miller T, Page RL 2nd, Peters L, Russell S, Scheel J, Schweiger M, Shullo M, Simpson K, Stuckey L, Tse T, Uber P, Weeks P, Weill D, Yost C
856			_uhttps://dx.doi.org/10.1016/j.healun.2020.06.024 _zhttps://dx.doi.org/10.1016/j.healun.2020.06.024
942			_cART _dArticle
999			_c5617 _d5617